L. Hoover, C. Mininger, S. Rittenhouse; GlaxoSmithKline, Collegeville, PA. Lee Babrak, Bermudez; Oregon State Univ., Corvallis, OR. B-1311 R. Smeesters Commons

142 SCIENTIFIC SESSIONS September 9-12 | B-1297 Effects of Recombinant Thrombomodulin in Combination with Antibiotics on a Murine Legionella Pneumonia Model Y. Morinaga, K. Yanagihara, N. Kaku, Y. Migiyama, Y. Harada, K. Nagaoka, K. Yamada, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; Nagasaki Univ., Nagasaki, Japan. B-1298 Efficacy of Combination Therapy with Ciprofloxacin Plus Cefotaxime against Vibrio vulnificus Sepsis in Mice H. Jang, S. Jung, K. Park, J. Shin, S. Kang; Chonnam Natl. Univ. Coll. of Med., Gwang-Ju, Korea, Republic of. B-1299 Activity of Telavancin in Combination with Colistin in a Galleria mellonella Model of Acinetobacter baumannii Infection

M. Horsney

1 , L. Phee 1 , C. Longshaw 2 , D. Wareham 1 ; 1 QMUL, London, United Kingdom, 2 Astellas Europe, London, United Kingdom. B-1300 Activity of Tigecycline Combinations in Experimental Infections Caused by Nine KPC-Producing Enterobacteriaceae Clinical Isolates

G. Michail

1 , M. Labrou 1 , S. Manousaka 1 , A. Tsakris 2 , S. Pournaras 1 ; 1 Med. Sch., Univ. of Thessaly, Larissa, Greece, 2 Med. Sch., Univ. of Athens, Athens, Greece. B-1301 Efficacy of Solithromycin for Treatment of Experimental Syphilis Infection B. J. Molini, L. C. Tantalo, S. L. Brandt, S. K. Sahi, C. M. Marra, S. A. Lukehart; Univ. of Washington, Seattle, WA. B-1302 Efficacy of Plazomicin against Yersinia pestis in a Murine- Aerosol Challenge Late-Treatment Model

H. S. Heine

1 , L. Chuvala 1 , R. Riggins 1 , G. Hurteau 1 , R. Cass 2 , R. Cirz 2 ; 1 Univ. of Florida, Gainesville, FL, 2 Achaogen Inc., San Francisco, CA. B-1303 In Vitro and In Vivo Activity of Modithromycin EDP-420 against Neisseria gonorrhoeae

X. Luo

1 , L. T. Phan 1 , O. Jones-Nelson 2 , M. Pilligua-Lucas 2 , D. J. J. Simon 2 , A. E. Jerse 2 , Y. S. Or 1 ; 1 ENANTA Pharmaceuticals, Inc., Watertown, MA, 2 Uniformed Services Univ., Bethesda. B-1304 Efficacy of a Novel Mechanism Antibacterial GSK2251052 against Yersinia pestis in a Post-Exposure Prophylaxis Murine- Aerosol Challenge Model

H. S. Heine

1 , L. Chuvala 1 , R. Riggins 1 , G. Hurteau 1 , C. Jakielaszek 2 ; 1 Univ. Florida, Gainesville, FL, 2 GlaxoSmithKline, Collegeville, PA. B-1305 Colonization Characteristics of Quinolone-Resistant Esch- erichia coli in the Faecal Microbiota of Healthy Volunteers

V. de Lastours

1 , A. Bleibtreu 2 , F. Chau 1 , E. Denamur 2 , B. Fantin 3 ; 1 EA3964 Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France, 2 UMR U772 Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France, 3 EA3964 Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France. B-1306 Clinical Impact of Aac6’-Ib-cr on Ciprofloxacin Treatment in a Murine Model of Escherichia coli Pyelonephritis

T. Guillard

1 , E. Cambau 1 , F. Chau 1 , C. de Champs 2 , B. Fantin 1 ; 1 Univ Paris Diderot-Paris 7, Paris, France, 2 SFR CAP-Santé , URCA, Reims, France. B-1307 Mediation of the Development of Periodontitis by Amino- guanidine

P. Chang, Chang, L. Chong, S. Tsai; Natl. Univ. of Singapore, Singapore, Singapore.

B-1308 GSK2251052, a Novel LeuRS Inhibitor, is Effective against Multidrug-Resistant Pseudomonas aeruginosa in a Mouse Pneu- monia Model

J. L. Hoover, C. Mininger, S. Rittenhouse; GlaxoSmithKline, Collegeville, PA.

Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 165 B Poster Session Microbial Determinants of Virulence Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: B-1309 Sequence Analysis of RepMP4 and RepMP23 Elements of Mycoplasma pneumoniae P1 Gene During Four Outbreaks Between 2000 and 2011

J. Lee

1 , N. Yang 2 , K. Hong 2 , E. Choi 3 , H. Lee 3 ; 1 Kangwon Natl. Univ. Hosp., Chuncheon, Korea, Republic of, 2 Seoul Natl. Univ. Children’s Hosp., Seoul, Korea, Republic of, 3 Coll. of Med., Seoul Natl. Univ., Seoul, Korea, Republic of. B-1310 Identification of Mycobacterium avium ssp hominissuis MAH Genes Related to the Formation of Microaggregates as Putative Targets for Prevention of Lung Infection L. Babrak, L. Bermudez; Oregon State Univ., Corvallis, OR. B-1311 Streptococcus pyogenes Protease, SpyCEP, Interrupts CXC Neutrophil Chemoattractant Signalling by Preventing CXCR12 Receptor Binding J. Goldblatt, E. Wise, J. Viney, N. Lynskey, C. Turner, R. Edwards, J. Pease, S. Sriskandan; Imperial, London, United Kingdom. B-1312 Toward a Functional Classification of Group A Streptococcus M Protein

P. R. Smeesters

1,2,3 , K. Sriprakash 3 , P. Dreze 1 , T. Vu, 3 , D. Bessen 4 , J. Gug- lielmini 5 , A. Steer 2 , J. Carapetis 6 , L. Van Melderen 1 , D. McMillan 3 , M Pro- tein Study Group; 1 Univ. Libre de Bruxelles, Charleroi, Belgium, 2 Murdoch Children Res. Inst., Melbourne, Australia, 3 Queensland Inst. for Med. Res., Brisbane, Australia, 4 New York Med. Coll., New-York, NY, 5 Inst. Pasteur, Paris, France, 6 Menzies Sch. of Hlth. Res., Darwin, Australia. B-1313 A Framework for Streptococcal Superantigen Nomenclature and Disease Association

R. Commons

1 , P. R. Smeesters 2 , N. Curtis 3 ; 1 Royal Darwin Hosp., Northern Territory, Australia, 2 Murdoch Children’s Res. Inst., Parkville, Australia, 3 The Univ. of Melbourne and Murdoch Children’s Res. Inst., Royal Children’s Hosp. Melbourne, Parkville, Australia. B-1314 Genomic Comparison of Streptococcus mitis and Streptococcus pneumoniae

A. M. Mitchell